Jim Simons Tricida, Inc. Transaction History

Renaissance Technologies LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.14 - $12.49 $30,950 - $2.76 Million	221,074 Added 1298.45%	238,100 $36,000
Q3 2022 Nov 14, 2022	SELL	$8.51 - $13.6 $128,279 - $205,006	-15,074 Reduced 46.96%	17,026 $178,000
Q2 2022 Aug 12, 2022	SELL	$7.31 - $11.85 $216,376 - $350,760	-29,600 Reduced 47.97%	32,100 $311,000
Q1 2022 May 13, 2022	SELL	$7.35 - $10.63 $205,873 - $297,746	-28,010 Reduced 31.22%	61,700 $507,000
Q4 2021 Feb 11, 2022	SELL	$4.19 - $9.56 $105,965 - $241,772	-25,290 Reduced 21.99%	89,710 $858,000
Q3 2021 Nov 12, 2021	BUY	$3.56 - $4.64 $128,067 - $166,919	35,974 Added 45.52%	115,000 $534,000
Q2 2021 Aug 13, 2021	SELL	$3.95 - $5.41 $446,215 - $611,146	-112,966 Reduced 58.84%	79,026 $341,000
Q1 2021 May 13, 2021	BUY	$4.52 - $7.8 $416,350 - $718,481	92,113 Added 92.22%	191,992 $1.02 Million
Q4 2020 Feb 10, 2021	BUY	$4.37 - $9.46 $436,471 - $944,855	99,879 New	99,879 $704,000
Q3 2020 Nov 13, 2020	SELL	$8.56 - $26.93 $1.38 Million - $4.33 Million	-160,717 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$21.21 - $31.55 $910,269 - $1.35 Million	42,917 Added 36.43%	160,717 $4.42 Million
Q1 2020 May 14, 2020	BUY	$18.43 - $38.04 $1.61 Million - $3.33 Million	87,600 Added 290.07%	117,800 $2.59 Million
Q4 2019 Feb 13, 2020	BUY	$29.6 - $43.71 $893,920 - $1.32 Million	30,200 New	30,200 $1.14 Million
Q3 2019 Nov 13, 2019	SELL	$29.87 - $42.22 $229,999 - $325,094	-7,700 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$31.16 - $39.46 $239,932 - $303,842	7,700 New	7,700 $304,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.